ArticleCancer discovery2019

Polyclonal Heterogeneity: The New Norm for Secondary Clinical Resistance to Targeted Monotherapy in Relapsed Leukemia?

Andrew H Wei et al.PubMed ↗Publisher ↗

No numbers read from the abstract.